The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters.
Nanion now introduces "Nanion Approved Cells", where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance for automated patch clamp.
Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion's existing products which until now covered ion channels and nanopores.
Today, Nanion celebrates 10 years of innovation, scientific product development and successful roll-outs of several product families. Nanion is a success story of organic, revenue-based company growth and dedicated young professionals.
Today, Nanion announces the opening of yet another branch. To meet the needs of the rapidly expanding number of customers in China, the dedicated sales- and support team in Beijing now opens the doors to Nanion Technologies China.
The Patchliner and the SyncroPatch 96 have successfully been used for compound analysis under current- and voltage clamp recording conditions using different stem cell-derived cardiomyocytes. The exceptional cell-platform-compatibility and the unique experimental possibilities offered by Nanion's platforms open up whole new avenues for compound safety testing.
Satisfied Users & 
Approved Press Releases
